Gina Tomaine

News

Real-World Treatment Patterns and Outcomes in Newly Diagnosed MCL

08/02/2022

Findings from a retrospective study show 1 in 4 young patients with MCL received first-line cytarabine followed by autoHSCT in the real-world setting, suggesting a need for novel treatments in routine clinical practice.

Findings from a retrospective...

08/02/2022

Oncology

Conference Coverage

Venetoclax Plus Azacitidine Sustains OS Benefit for Patients With AML Ineligible for Intensive Chemotherapy

12/11/2022

Gina Tomaine ;

Long-term follow-up results from the phase 3 VIALE-A trial show sustained OS benefit with venetoclax plus azacitidine vs placebo plus azacitidine for patients with AML ineligible for intensive chemotherapy.

Long-term follow-up results from...

12/11/2022

Oncology

News

BTK Inhibitor Orelabrutinib Demonstrates Efficacy, Safety for Patients With R/R Mantle Cell Lymphoma

09/29/2023

Gina Tomaine ;

Orelabrutinib was effective and well-tolerated among patients with relapsed/refractory mantle cell lymphoma, according to a phase 1/2 study.

Orelabrutinib was effective and...

09/29/2023

Oncology

News

Red Blood Cell Transfusion Commonly Required For Patients With Myelofibrosis Receiving Ruxolitinib

08/10/2022

Gina Tomaine ;

Study findings reveal red blood cell transfusion is often required during ruxolitinib treatment for patients with myelofibrosis, particularly among those who underwent ≥ 2 units of red blood cell transfusion over 8 weeks.

Study findings reveal red blood...

08/10/2022

Oncology

News

Sugemalimab Monotherapy for Patients With R/R Extranodal Natural Killer/T-Cell Lymphoma

04/25/2023

Gina Tomaine ;

Sugemalimab treatment was well-tolerated and demonstrated robust and durable antitumor activity among patients with relapsed/refractory extranodal natural killer/T-cell lymphoma, according to a recent phase 2 study.

Sugemalimab treatment was...

04/25/2023

Oncology

News

Transplantation Added to RVD Yields Longer PFS Than RVD Alone in Patients With MM

07/18/2022

Gina Tomaine ;

Among adults with MM, treatment with lenalidomide, bortezomib, and dexamethasone (RVD) and autologous stem-cell transplantation was associated with longer PFS than RVD alone, according to a phase 3 trial.

Among adults with MM, treatment...

07/18/2022

Oncology

News

09/07/2023

Gina Tomaine ;

The rituximab biosimilar, SDZ-RTX, combined with a CHOP regimen was effective and well-tolerated as a frontline treatment for patients with diffuse large B-cell lymphoma (DLBCL), according to a real-world study.

The rituximab biosimilar,...

09/07/2023

Oncology

News

Brexucabtagene Autoleucel Yields Durable Long-term Responses in MCL: 3-Year Follow-up From ZUMA-2

08/02/2022

Gina Tomaine ;

Brexucabtagene autoleucel induced durable long-term responses with manageable safety in patients with relapsed/refractory MCL, according to a 3-year follow-up analysis of the ZUMA-2 study.

Brexucabtagene autoleucel...

08/02/2022

Oncology

News

Momelotinib Superior to Danazol in Symptomatic and Anemic Myelofibrosis Patients Previously Treated With JAK Inhibitor

11/17/2022

Gina Tomaine ;

Momelotinib improved symptom responses, transfusion requirements, and spleen responses for symptomatic and anemic myelofibrosis patients previously treated with a JAK inhibitor when compared with danazol, according to the phase 3 MOMENTUM...

Momelotinib improved symptom...

11/17/2022

Oncology

News

FDA Approves Zanubrutinib for Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

04/24/2023

Gina Tomaine ;

On January 19, 2023, the Food and Drug Administration (FDA) approved zanubrutinib for chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). This approval was based on the SEQUOIA and ALPINE trials, respectively. The...

On January 19, 2023, the Food...

04/24/2023

Journal of Clinical Pathways